Gastroesophageal reflux disease (GERD) is arguably the most common chronic gastrointestinal disorder, characterized by symptoms of heartburn and regurgitation. The primary objectives of GERD treatment are to provide symptom relief, heal erosive esophagitis, and prevent future complications. Available treatment options for GERD are limited; over-the-counter (OTC) antacids are frequently used for acute symptom relief, while proton pump inhibitors (PPIs) have remained the mainstay of chronic therapy, along with lifestyle modifications. However, there is growing concern regarding the side effects associated with long-term use of PPIs, and the number of patients who are nonresponsive to PPIs is increasing, leading to possible shifts in the treatment approach. This report provides insights into current patient-level drug-prescribing patterns among newly diagnosed and recently treated GERD patients.
Longitudinal patient-level claims data analysis
Key drugs covered
Proton pump inhibitors, histamine H2-receptor antagonists, antacids, and gastroprokinetic agents
Key analysis provided
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.